Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Facility

LOS ANGELES, Oct. 16, 2023

Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”) today announced the successful completion of its 3rd engineering batch of NXC-201 at its state-of-the-art cellular immunotherapy manufacturing facility in California. This milestone marks a significant step forward in the company’s ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial expansion to the U.S.

Advancements in CAR-T Therapy

CAR-T therapy is a groundbreaking form of cancer treatment that harnesses the body’s immune system to target and destroy cancer cells. NXC-201 is a novel CAR-T therapy developed by Immix Biopharma, with promising results in the treatment of various forms of cancer.

The successful completion of the 3rd engineering batch of NXC-201 signifies the company’s commitment to advancing the field of cellular immunotherapy and bringing innovative treatment options to patients in need.

Impact on Patients

Patients who are eligible for participation in the NEXICART-1 clinical trial will now have access to NXC-201 therapy manufactured right here in the U.S. This localization of manufacturing ensures a streamlined process for patients, reducing wait times and allowing for faster treatment initiation.

Furthermore, the completion of the engineering batch signals progress towards making NXC-201 more widely available to patients in the future, potentially revolutionizing the way certain cancers are treated.

Global Implications

The expansion of the NEXICART-1 NXC-201 CAR-T clinical trial to the U.S. signifies a step towards global accessibility of this cutting-edge therapy. As more patients benefit from CAR-T treatments like NXC-201, the landscape of cancer treatment worldwide may be forever changed.

How Does This Affect Me?

As a potential patient in need of advanced cancer treatment, the completion of the 3rd engineering batch of NXC-201 at Immix Biopharma’s U.S. manufacturing facility means you now have access to a promising new therapy that could significantly impact your treatment journey.

Global Impact

The expansion of the NXC-201 CAR-T clinical trial to the U.S. represents a major milestone in the field of cellular immunotherapy. As more patients benefit from these cutting-edge treatments, the global landscape of cancer care may see significant advancements in the coming years.

Conclusion

The successful completion of the 3rd engineering batch of NXC-201 at Immix Biopharma’s U.S. manufacturing facility marks a significant advancement in the field of CAR-T therapy. With implications for both individual patients and the global community, this milestone signifies a promising future for the treatment of cancer.